Research library
Sources, with the status on the record.
Each row is a paper or a ClinicalTrials.gov entry checked on 21 November 2026. Titles are the authors’ or the registry’s words. Nalen Lab does not restate them as claims about these products. A registration is not a result.
Records checked 2026-11-21. Open registry rows in this view: 8. Selank has published papers and no verified intervention trial.
Loading filters…
BPC-157
2011
Publication
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.
Chang CH et al. · Journal of Applied Physiology
PublishedSame compound as the catalogue listing
Preclinical paper. The title is the authors' wording, not a Nalen Lab claim.
View in the catalogueBPC-157
2003
Publication
Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.
Staresinic M et al. · Journal of Orthopaedic Research
PublishedSame compound as the catalogue listing
Rat and in-vitro experiments.
View in the catalogueBPC-157
2016
Publication
Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.
Sikiric P et al. · Current Neuropharmacology
PublishedSame compound as the catalogue listing
Review.
View in the catalogueBPC-157
2021
Publication
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.
Seiwerth S et al. · Frontiers in Pharmacology
PublishedSame compound as the catalogue listing
Review.
View in the catalogueBPC-157
2026
Registry
BPC 157 for Acute Hamstring Muscle Strain Repair
Phase 2 · ClinicalTrials.gov · NCT07437547 · Hudson Biotech
RecruitingSame compound as the catalogue listing
Registry record checked 21 November 2026. A registration is not a result. Status can change; the link is the source of truth.
View in the catalogueBPC-157
2026
Registry
Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery
Phase 1 · ClinicalTrials.gov · NCT07803250 · University of Arkansas
Not yet recruitingSame compound as the catalogue listing
Listed start date 1 January 2027. Not yet recruiting when checked on 21 November 2026.
View in the catalogueBPC-157
2015
Registry
PCO-02 - Safety and Pharmacokinetics Trial
Phase 1 · ClinicalTrials.gov · NCT02637284 · PharmaCotherapia d.o.o.
UnknownSame compound as the catalogue listing
Official title names BPC-157 (Bepecin) as the active ingredient of oral PCO-02. ClinicalTrials.gov status is Unknown. Last update posted December 2015. Not counted as an active trial.
View in the catalogueTB-500
2012
Publication
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.
Esposito S et al. · Drug Testing and Analysis
PublishedSame compound as the catalogue listing
Analytical characterisation of the fragment sold as TB-500. It is not a clinical efficacy study.
View in the catalogueTB-500
1999
Publication
Thymosin beta4 accelerates wound healing.
Malinda KM et al. · Journal of Investigative Dermatology
PublishedRelated molecule — not the catalogue compound
This paper studies full-length thymosin β4, not the acetylated 17–23 fragment named TB-500 in the Nalen Lab catalogue.
View in the catalogueTB-500
2012
Publication
Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications.
Goldstein AL et al. · Expert Opinion on Biological Therapy
PublishedRelated molecule — not the catalogue compound
Review of full-length thymosin β4, not the TB-500 fragment.
View in the catalogueTB-500
2026
Registry
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
Phase 1/2 · ClinicalTrials.gov · NCT07487363 · Hudson Biotech
RecruitingSame compound as the catalogue listing
The record names the 17–23 fragment. Checked 21 November 2026. A registration is not a result.
View in the catalogueTB-500
2023
Registry
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
Phase 3 · ClinicalTrials.gov · NCT05555589 · ReGenTree, LLC
CompletedRelated molecule — not the catalogue compound
RGN-259 is an ophthalmic solution of thymosin β4 (Tβ4), not the TB-500 fragment. Status Completed when checked on 21 November 2026.
View in the catalogueTB-500
2011
Registry
Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye
Phase 2 · ClinicalTrials.gov · NCT01387347 · ReGenTree, LLC
CompletedRelated molecule — not the catalogue compound
Full-length thymosin β4 eye drops, not the TB-500 fragment.
View in the catalogueCJC-1295 without DAC
2006
Publication
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Teichman SL et al. · Journal of Clinical Endocrinology & Metabolism
PublishedDifferent form from the catalogue listing
This study used long-acting CJC-1295 (the DAC form). The without-DAC catalogue listing is a different molecule. The same paper is also filed under CJC-1295 with DAC.
View in the catalogueCJC-1295 without DAC
2009
Publication
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
Sackmann-Sala L et al. · Growth Hormone & IGF Research
PublishedDifferent form from the catalogue listing
Long-acting (DAC) analogue. Filed under the without-DAC listing as a different form, and under the with-DAC listing as the same form.
View in the catalogueCJC-1295 without DAC
2005
Registry
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
Phase 2 · ClinicalTrials.gov · NCT00267527 · ConjuChem
TerminatedDifferent form from the catalogue listing
Terminated. The sponsor's CJC-1295 programme used the long-acting DAC form, not Mod GRF 1–29. Also filed under CJC-1295 with DAC.
View in the catalogueIpamorelin
1998
Publication
Ipamorelin, the first selective growth hormone secretagogue.
Raun K et al. · European Journal of Endocrinology
PublishedSame compound as the catalogue listing
Pharmacology paper in vitro and in animals. DOI 10.1530/eje.0.1390552.
View in the catalogueIpamorelin
1999
Publication
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.
Gobburu JV et al. · Pharmaceutical Research
PublishedSame compound as the catalogue listing
View in the catalogueIpamorelin
1999
Publication
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.
Johansen PB et al. · Growth Hormone & IGF Research
PublishedSame compound as the catalogue listing
Rat study. The title is the authors' wording.
View in the catalogueIpamorelin
2011
Registry
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
Phase 2 · ClinicalTrials.gov · NCT01280344 · Helsinn Therapeutics (U.S.), Inc
CompletedSame compound as the catalogue listing
Completed. No recruiting ipamorelin trial was verified on 21 November 2026.
View in the catalogueIpamorelin
2008
Registry
Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus
Phase 2 · ClinicalTrials.gov · NCT00672074 · Helsinn Therapeutics (U.S.), Inc
CompletedSame compound as the catalogue listing
View in the catalogueMOTS-c
2015
Publication
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
Lee C et al. · Cell Metabolism
PublishedSame compound as the catalogue listing
Founding paper. Mouse and cell work. The title is the authors' wording.
View in the catalogueMOTS-c
2022
Publication
MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases.
Mohtashami Z et al. · International Journal of Molecular Sciences
PublishedSame compound as the catalogue listing
Review.
View in the catalogueMOTS-c
2026
Registry
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
Phase 2 · ClinicalTrials.gov · NCT07505745 · Hudson Biotech
RecruitingSame compound as the catalogue listing
Intervention named on the record is MOTS-c. Checked 21 November 2026. A registration is not a result.
View in the catalogueMOTS-c
2014
Registry
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
Observational · ClinicalTrials.gov · NCT04027712 · University of Athens
UnknownMeasures or combines the compound; not a single-compound vial study
This record follows endogenous MOTS-c as a measured marker. It does not administer the peptide. Status Unknown. Not an active treatment trial.
View in the catalogueGHK-Cu
2018
Publication
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.
Pickart L et al. · International Journal of Molecular Sciences
PublishedSame compound as the catalogue listing
Review. The title is the authors' wording.
View in the catalogueGHK-Cu
2015
Publication
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.
Pickart L et al. · BioMed Research International
PublishedSame compound as the catalogue listing
Review.
View in the catalogueGHK-Cu
2012
Publication
The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health.
Pickart L et al. · Oxidative Medicine and Cellular Longevity
PublishedSame compound as the catalogue listing
Review.
View in the catalogueGHK-Cu
2026
Registry
Topical GHK-Cu Gel for Acute Skin Wound Healing
Phase 2 · ClinicalTrials.gov · NCT07437586 · Hudson Biotech
RecruitingSame compound as the catalogue listing
Topical gel, not a lyophilised vial. Checked 21 November 2026.
View in the catalogueGHK-Cu
2026
Registry
Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults
Not applicable · ClinicalTrials.gov · NCT07706361 · LifeWave, Inc.
Not yet recruitingMeasures or combines the compound; not a single-compound vial study
The intervention is a patch. The record measures circulating GHK and GHK-Cu. It does not administer a GHK-Cu vial.
View in the catalogueGHK-Cu
2026
Registry
Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks
Early phase 1 · ClinicalTrials.gov · NCT07888595 · Frontiers in Bioscience Research Institute and Aging
Enrolling by invitationMeasures or combines the compound; not a single-compound vial study
One record covers several agents. The topical serum is described as containing GHK-Cu, AHK-Cu, Epitalon, PGP and CLV, alongside other agents taken by mouth or injection. Not a GHK-Cu-only trial. Also listed under Epitalon.
View in the catalogueSelank
2017
Publication
Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.
Kasian A et al. · Behavioural Neurology
PublishedSame compound as the catalogue listing
Rat study. The title is the authors' wording.
View in the catalogueSelank
2019
Publication
Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.
Kolik LG et al. · Bulletin of Experimental Biology and Medicine
PublishedSame compound as the catalogue listing
Rat study.
View in the catalogueSelank
2020
Publication
Functional Connectomic Approach to Studying Selank and Semax Effects.
Panikratova YR et al. · Doklady Biological Sciences
PublishedSame compound as the catalogue listing
The paper also discusses Semax, which is not in the Nalen Lab catalogue.
View in the catalogueEpitalon
2003
Publication
Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells.
Khavinson VKh et al. · Bulletin of Experimental Biology and Medicine
PublishedSame compound as the catalogue listing
Cell-culture paper. Epithalon is the spelling used on the record. The title is the authors' wording.
View in the catalogueEpitalon
2006
Publication
Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice.
Kossoy G et al. · In Vivo
PublishedSame compound as the catalogue listing
Mouse study.
View in the catalogueEpitalon
2025
Publication
Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties.
Araj SK et al. · International Journal of Molecular Sciences
PublishedSame compound as the catalogue listing
Review. The title is the authors' wording.
View in the catalogueEpitalon
2026
Registry
Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks
Early phase 1 · ClinicalTrials.gov · NCT07888595 · Frontiers in Bioscience Research Institute and Aging
Enrolling by invitationMeasures or combines the compound; not a single-compound vial study
Same record as the GHK-Cu row. The topical serum is described as containing Epitalon among other peptides, plus other agents. Not an Epitalon-only trial.
View in the catalogueCJC-1295 with DAC
2006
Publication
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Teichman SL et al. · Journal of Clinical Endocrinology & Metabolism
PublishedSame compound as the catalogue listing
Human study of the long-acting (DAC) form. The title is the authors' wording.
View in the catalogueCJC-1295 with DAC
2009
Publication
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
Sackmann-Sala L et al. · Growth Hormone & IGF Research
PublishedSame compound as the catalogue listing
Long-acting (DAC) analogue.
View in the catalogueCJC-1295 with DAC
2005
Registry
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
Phase 2 · ClinicalTrials.gov · NCT00267527 · ConjuChem
TerminatedSame compound as the catalogue listing
Terminated. The sponsor's programme used the long-acting DAC form.
View in the catalogueTesamorelin
2021
Publication
Tesamorelin improves fat quality independent of changes in fat quantity.
Lake JE et al. · AIDS
PublishedSame compound as the catalogue listing
Clinical paper in adults with HIV. The title is the authors' wording, not a Nalen Lab claim.
View in the catalogueSermorelin
1999
Publication
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
Prakash A et al. · BioDrugs
PublishedSame compound as the catalogue listing
Review of the authorised diagnostic use. The title is the journal's wording.
View in the catalogueSemax
2021
Publication
Brain Protein Expression Profile Confirms the Protective Effect of the ACTH((4-7))PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion.
Sudarkina OY et al. · International Journal of Molecular Sciences
PublishedSame compound as the catalogue listing
Rat study. The title is the authors' wording.
View in the catalogueSemaglutide
2021
Publication
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH et al. · New England Journal of Medicine
PublishedSame compound as the catalogue listing
STEP 1 trial of the authorised medicine. The title is the authors' wording. It is not a description of a Nalen Lab vial.
View in the catalogueTirzepatide
2022
Publication
Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM et al. · New England Journal of Medicine
PublishedSame compound as the catalogue listing
SURMOUNT-1 trial of the authorised medicine. The title is the authors' wording.
View in the catalogueRetatrutide
2023
Publication
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM et al. · New England Journal of Medicine
PublishedSame compound as the catalogue listing
Phase 2 trial. The title is the authors' wording. A registration is not implied by this paper.
View in the cataloguePT-141
2022
Publication
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
Simon JA et al. · Journal of Women's Health
PublishedSame compound as the catalogue listing
Phase 3 analyses of the authorised medicine bremelanotide. The title is the authors' wording.
View in the catalogueMelanotan II
2026
Publication
Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report.
Bonchev A et al. · Life (Basel)
PublishedSame compound as the catalogue listing
Single case report. The title is the authors' wording.
View in the catalogueKisspeptin-10
2025
Publication
Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans.
Mills EG et al. · eBioMedicine
PublishedSame compound as the catalogue listing
Human study. The title is the authors' wording.
View in the catalogueAOD-9604
2015
Publication
Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.
Kwon DR et al. · Annals of Clinical & Laboratory Science
PublishedSame compound as the catalogue listing
Rabbit study. The title is the authors' wording.
View in the catalogueDSIP
2021
Publication
Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke.
Tukhovskaya EA et al. · Molecules
PublishedSame compound as the catalogue listing
Rat study. The title is the authors' wording.
View in the catalogueThymosin Alpha-1
2024
Publication
Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials.
Dinetz E et al. · Alternative Therapies in Health and Medicine
PublishedSame compound as the catalogue listing
Review. The title is the authors' wording.
View in the catalogueKPV
2017
Publication
Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.
Pawar K et al. · Journal of Pharmaceutical Sciences
PublishedSame compound as the catalogue listing
Skin-permeation study, not a clinical efficacy trial.
View in the catalogueNAD+
2018
Publication
Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.
Rajman L et al. · Cell Metabolism
PublishedSame compound as the catalogue listing
Review of NAD metabolism and NAD-boosting molecules. It is not a test of a lyophilised NAD+ vial.
View in the catalogue